KTOV vs. LIXT, ASLN, BFRI, TFFP, BNOX, UPC, CMMB, KTTA, KA, and HEPA
Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Lixte Biotechnology (LIXT), ASLAN Pharmaceuticals (ASLN), Biofrontera (BFRI), TFF Pharmaceuticals (TFFP), Bionomics (BNOX), Universe Pharmaceuticals (UPC), Chemomab Therapeutics (CMMB), Pasithea Therapeutics (KTTA), Kineta (KA), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "medical" sector.
Purple Biotech (NASDAQ:KTOV) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Lixte Biotechnology has lower revenue, but higher earnings than Purple Biotech. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Purple Biotech has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500.
Purple Biotech's return on equity of 0.00% beat Lixte Biotechnology's return on equity.
In the previous week, Lixte Biotechnology had 2 more articles in the media than Purple Biotech. MarketBeat recorded 2 mentions for Lixte Biotechnology and 0 mentions for Purple Biotech. Lixte Biotechnology's average media sentiment score of 0.09 beat Purple Biotech's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the news media.
30.7% of Purple Biotech shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by company insiders. Comparatively, 15.5% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Purple Biotech received 211 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.
Summary
Purple Biotech beats Lixte Biotechnology on 7 of the 12 factors compared between the two stocks.
Get Purple Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Purple Biotech Competitors List
Related Companies and Tools
